Skip to main content

NIDDK's $15M Grant Program to Fund 'Omics

NEW YORK (GenomeWeb News) – The National Institute of Diabetes and Digestive and Kidney Diseases will award up to $15 million next year in grants to fund Diabetes Research Centers that will conduct a range of 'omics-based and other interdisciplinary and translational research efforts.

The grants will provide up to $1 million per year in direct costs to fund the centers, but if the institutions are willing to serve as Regional/National Shared Resource Core Centers the grants will provide up to $1.3 million per year.

These NIDDK centers will perform and support cutting-edge research in diabetes and in related areas of metabolism, seek to foster synergy between basic scientists and clinical investigators, and promote progress toward a cure for diabetes and its complications.

The centers will have three primary functions: the Research Core Services that provide resources to the NIDDK's research efforts; a Pilot and Feasibility Program to foster development of new investigators and provide seed support for innovative projects; and an Enrichment Program to promote interdisciplinary interactions and training of researchers engaged in NIDDK's areas of interest.

The research cores will provide services to multiple funded projects, and the centers may propose to share core services or functions with other centers in the program, or to expand, enhance, or increase the cost-effectiveness of the center's activities.

These grants will fund a broad array of research approaches and research cores engaged in: genetics, genomics, and epigenetics; proteomics; metabolomics; protein chemistry and macromolecular structure; bioinformatics; clinical research; imaging; and other fields of study.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.